Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT03487913 is registered in ClinicalTrials.gov with Palladio Biosciences as lead sponsor.

NCT NCT03487913
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03487913 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Lead sponsor
Palladio Biosciences
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2018
Completion date
February 11, 2020
Enrollment
31 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney disease